The Effects of Antibiotic Exposure in Early Infancy on Vaccine Responses
NCT ID: NCT06079606
Last Updated: 2025-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
200 participants
OBSERVATIONAL
2022-09-10
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The cohort will be divided into the following groups:
* Group A: Term children born with elective caesarean section (their mothers received intra-operative antibiotics).
* Group B: Term vaginally born children and their mothers received intra-partum antibiotics.
* Group C: Term vaginally born children that received systemic antibiotics during the first week of life for at least 48 hours.
* Group D: Term vaginally born children that had not received systemic antibiotics at the time of recruitment.
Parents of children born with elective caesarean section in Landspitali or born vaginally and their mothers received intra-partum antibiotics as well as parents of children in the Neonatal Intensive Care Unit receiving systemic antibiotics during the first week of life will be offered to take part in the study (Groups A, B and C). Parents of children coming to a five day old check up at the Children's Hospital in Landspitali will also be offered to take part in the study (Group D). Sample size calculations show that to detect a 30% difference in immune responses to vaccines with 80% power, 40 infants are needed for analysis in each group. To account for late exclusions due to antibiotic use or drop-out due to other reasons, 50 infants will be recruited to each group. Participants will receive vaccination with the oral live attenuated rotavirus vaccine, Rotarix, at six weeks old and again at three months old. Participants will receive vaccinations with Pentavac against diphtheria, tetanus, pertussis, haemophilus influenza type B and polio and Synflorix against pneumococci at their Health Care Centre according to scheduled childhood vaccinations in Iceland at three, five and 12 months old. Salivary and blood samples will be taken from participants just before the first vaccination with Rotarix at six weeks old and again at six months (four weeks after the second dose of Pentavac and Synflorix) and at 13 months old (four weeks after the third dose of Pentavac and Synflorix). Specific antibody levels against rotavirus, pertussis, diphtheria, tetanus, haemophilus influenzae type B, polio virus and pneumococci will be measured. Parents of participants will be given two stool sample kits and asked to take one from their child at six weeks old (before the first dose of rotavirus vaccine) and then another at three months old. In case of detection of differences in antibody response, these samples will be sent for microbiome analysis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
Term children born with caesarean section (their mothers received intra-operative antibiotics)
Antibiotic treatment
Children will be assigned to groups according to antibiotic exposure in early life. No antibiotics will be given in the study.
Group B
Term vaginally born children and their mothers received intra-partum antibiotics
Antibiotic treatment
Children will be assigned to groups according to antibiotic exposure in early life. No antibiotics will be given in the study.
Group C
Term vaginally born children that received systemic antibiotics during the first week of life for at least 48 hours
Antibiotic treatment
Children will be assigned to groups according to antibiotic exposure in early life. No antibiotics will be given in the study.
Group D (Control group)
Term vaginally born children that had not received systemic antibiotics at the time of recruitment
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Antibiotic treatment
Children will be assigned to groups according to antibiotic exposure in early life. No antibiotics will be given in the study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Children born before 36 weeks of gestation
* Children diagnosed with primary or secondary immunodeficiency
* Use of immunosuppressive drugs at recruitment or during the follow up period (excluding inhaled corticosteroids and short term oral corticosteroids (\<3 consecutive days).
* Children with chromosomal, genetic or other congenital diseases or abnormalities
* Children with severe, chronic diseases or disabilities
* Informed consent not signed by parents
6 Weeks
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Landspitali University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Landspitali University Hospital
Reykjavik, , Iceland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
e-INFANT-2
Identifier Type: -
Identifier Source: org_study_id